Citations

Clear

1011 citation(s) found for "Barry, WT".

An engineered vaccine encompassing an MHC class I antigen presenting molecule induces self-reacting CTL in a setting of profound tolerance
Pease, Larry R. , Parks, Christopher A. , Kranz, David M. , Barry, Michael J.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 202 | Issue: 1_Supplement | Pages: 177.30-177.30

10.4049/jimmunol.202.supp.177.30 Get It

Abstract Engineered antigen presenting molecules can promote allorecognition and activate CTL capable of recognizing weak or self-antigens in the context of self-MHC. Traditionally, allogeneic antigen presenting molecules differ from self MHC molecules in their interactions with the bound peptides and with TCR expressed in the immune repertoire to promote peptide dependent alloimmunity. Alloreactive T cells target their inducing alloantigens, as well as third-party alloantigens, but as a result of tolerance, generally not self-antigen presenting molecules. Certain residues located on the alpha-1/2 domains of class I antigen presenting molecules interface with TCR CDR loops and do not influence the nature or orientation of bound peptides. These residues are more conserved within and across species than are residues that determine peptide antigen binding properties. Class I variants designed with amino acid substitutions at key positions within the conserved helical structures at this MHC:TCR interface are found to provide strong activating signals to alloreactive CD8 T cells in the self tolerant immune repertoire. We demonstrate that CTL activated in this manner can break self-tolerance by reacting to self-peptides presented by native MHC. The ability to activate self-tolerant T cells capable of cross-reacting on self-peptide-MHC in vivo represents a novel approach for inducing autoimmunity, with possible application the development of cancer vaccines.
Retargeting IgM Antibodies with Different Specificities to a Common Cell Type Reveals Shared Mechanisms Regulating Cellular Activation (91.12)
Keenan, Thomas D, Radhakrishnan, Suresh , Bell, Michael V., Pease, Larry R. , Keenan, Thomas D, Bell, Michael, Barry, Michael A

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 182 | Issue: 1_Supplement | Pages: 91.12-91.12

10.4049/jimmunol.182.supp.91.12 Get It

Abstract IgM antibodies, as multivalent ligands, have the capacity to activate cells differentially by cross-linking targeted cell surface signaling molecules. For example, hIgM12 (B7DC Xab) activates dendritic cells (DCs), leading to potent immunomodulation, while hIgM22 binds glial cells and causes remyelination in mouse models of multiple sclerosis. Both antibodies activate common signaling intermediates in their respective cellular targets suggesting a common mechanism of action. Elucidation of these shared mechanisms became possible by targeting both antibodies to a common cell type. Our previous studies demonstrate that B7-DC expression is required to activate downstream signaling in DCs by hIgM12. We utilized a phage display system to identify 7mer peptides bound by each IgM and expressed each peptide attached to a surrogate cell surface carrier on retrovirally tranduced bone marrow-derived DCs from B7-DC -/- mice. Transduced cells were treated with hIgM12, hIgM22 or anti-carrier IgM, and subsequent activity was compared against B7-DC +/+ DCs or B7-DC-reconstituted B7-DC -/- DCs. DC activation by each IgM was specific to expression of their conjugate peptide construct. Activation by hIgM22 was indistinguishable from activation by hIgM12, while anti-carrier IgM caused no activation. This indicates that while their target specificity differs, once bound these IgMs activate cells via common mechanisms.
Interleukin 1-mediated activation of interleukin 4 (IL 4)-producing T lymphocytes. Proliferation by IL 4-dependent and IL 4-independent mechanisms.
Ho, Seok , Abraham, Robert T. , Nilson, A, Handwerger, Barry S., McKean, D J, Ho, S N

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 139 | Issue: 5 | Pages: 1532-1540

10.4049/jimmunol.139.5.1532 Get It

Abstract The role of IL 1 in the activation of IL 4-producing murine T cell clones was investigated by using a calcium ionophore (ionomycin) or a phorbol ester (12-O-tetradecanoylphorbol 13-acetate; TPA) as T cell receptor-independent costimuli. The use of these pharmacologic agents to investigate IL 1-mediated T cell activation revealed two distinct mechanisms of activation. IL 1 in combination with ionomycin (iono/rIL 1) stimulated a proliferative response that was associated with the production of IL 4 as measured by lymphokine bioassay and mRNA studies. Furthermore, inhibition of this proliferative response with an anti-IL 4 monoclonal antibody or cyclosporine indicated that IL 4 functions as an autocrine growth factor. In contrast, IL 1 synergized with TPA (TPA/rIL 1) to induce proliferation in the absence of either IL 4 or IL 2 gene transcription or lymphokine secretion. The IL 4-independence of this activation mechanism was further supported by the failure of both anti-IL 4 antibodies and cyclosporine to inhibit the response. In addition, activation by TPA/rIL 1 caused no detectable alteration in cytoplasmic calcium levels. Both IL 4-dependent and IL 4-independent activation responses were associated with the expression of functional receptors for IL 2 as well as IL 4. Characterization of these activation responses suggests that the synergistic activity of IL 1 during T cell activation is multipotential. The nature of an IL 1-dependent T cell growth response, therefore, may vary depending on the balance of intracellular signals generated concurrently through the T cell receptor complex and other regulatory surface molecules.
The role of IL 1 in the antigen-specific activation of murine class II-restricted T lymphocyte clones.
McKean, D J, Nilson, A, Beck, Barbara, Giri, Judith G., Mizel, S B, Handwerger, Barry S., Beck, B N

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 135 | Issue: 5 | Pages: 3205-3216

10.4049/jimmunol.135.5.3205 Get It

Abstract The role of IL 1 in the antigen-specific activation of class II-restricted T lymphocytes was examined by using a model system consisting of cloned WEHI 5 B lymphoma accessory cells and class II-restricted, soluble antigen- or alloantigen-reactive T cell clones. The addition of exogenous recombinant IL 1 to the T cell cultures resulted in a significant enhancement of the antigen-specific T cell proliferation response, but at best, only small increases in IL 2 release. Goat IgG anti-IL 1 antibodies were added to the T cell cultures to assess their effect on T cell activation. The IL 1 enhancement of the T cell proliferation response was inhibited by the anti-IL 1 antibodies in a dose-dependent manner. In contrast, only modest levels (10 to 25%) of proliferation inhibition were observed in T cell cultures containing either WEHI 5 or splenocyte accessory cells but no exogenous IL 1. When the anti-IL 1 antibodies were added to primary mixed lymphocyte cultures stimulated by WEHI 5 cells in the absence of exogenous IL 1, no significant inhibition of proliferation was observed. A small but statistically significant proliferation inhibition was observed when anti-IL 1 antibodies were added to mixed lymphocyte reaction cultures stimulated by splenocytes. Two-color cytofluorometric analysis of the effects of IL 1 on antigen-activated T cell clones demonstrated that under suboptimal stimulation conditions, IL 1 stimulated a small but significant increase in the number of T cells bearing IL 2 receptors. In the presence of optimal numbers of WEHI 5 accessory cells, IL 1 enhanced T cell proliferation in the absence of a detectable increase in the number of T cells bearing IL 2 receptors, the number of IL 2 receptors per T cell, or the levels of IL 2 released. Finally, exogenous IL 1 can be added as late as 18 to 24 hr after culture initiation without significantly reducing its ability to enhance the T cell proliferation response. These data indicate that IL 1 has pleiotropic effects on murine T lymphocytes and can function to enhance T cell activation at multiple points during the activation sequence.
Characterization of murine T cell activation signals produced by B lymphoma cells.
McKean, D J, Nilson, A, Beck, Barbara, Mizel, S B, Handwerger, Barry S., Beck, B N

Mayo Clinic

The Journal of Immunology | December 31, 2022 | Volume: 134 | Issue: 4 | Pages: 2484-2491

10.4049/jimmunol.134.4.2484 Get It

Abstract The activation requirements of alloreactive and antigen reactive murine T cells were examined by stimulating class II restricted T cell clones with monoclonal B lymphoma cells. One B lymphoma cell line (T27A) was found to stimulate IL 2 release from some alloreactive T cell clones without stimulating any significant T cell proliferation response. The same B lymphoma cells are capable of stimulating IL 2 release and proliferative responses from other T cell clones. Evidence is presented suggesting that B lymphoma cell stimulation of these T cell clones is largely IL 1 independent and that at least some T cell clones may require activation signals other than Ia, antigen, and IL 1. The addition of exogenous, purified IL 1 to the T cell activation assays was found to have a wide range of stimulatory effects on the proliferative responses of different T cell clones. The absence of comparable IL 1-induced stimulation of IL 2 secretion suggests that IL 1 primarily enhances antigen specific T cell proliferation through mechanisms other than acting as a co-stimulant for IL 2 release.
Comparison of Binding of IgE and IgG Antibodies to Honeybee Venom Phospholipase-A
Paull, Barry R., Jacob, G.L., Yunginger, John W., Gleich, Gerald J.

Mayo Clinic

The Journal of Immunology | December 30, 2022 | Volume: 120 | Issue: 6 | Pages: 1917-1923

10.4049/jimmunol.120.6.1917 Get It

Abstract We compared the quantities and avidities of IgE and IgG antibodies from three phospholipase-A (PLA) sensitive patients during honeybee venom immunotherapy. IgG antibody was purified by affinity chromatography through a Sepharose anti-IgE Column followed by ionexchange chromatography on DEAE Sephadex. IgE antibody was obtained by elution from the Sepharose anti-IgE column with 4 M guanidinium HCl and by passage of the eluate over Sepharose anti-IgG. Absolute amounts of IgE and IgG antibody to PLA were determined by immunoabsorption and radioimmunoprecipitation, respectively. IgE antibody to PLA accounted for 25.1% to 28.7% (X̄ = 27.0%) of the total IgE protein; IgG antibody accounted for 0.073% to 0.210% (X̄ = 0.130%) of the total IgG protein. The relative avidities of IgE and IgG antibodies were assessed by the ability of equimolar amounts to bind radioiodinated PLA. In two patients, avidities of IgE and IgG antibody for PLA were comparble, whereas in the third, IgG antibody bound PLA more avidly than IgE antibody. The valence of IgE antibody was greater than 1.9, assuming that PLA behaved as a univalent ligand in extreme antigen excess. IgG antibody was able to inhibit binding of IgE antibody in the PLA radioallergosorbent test (RAST) from 10% to 40% at a molar excess of 10- to 1000-fold. The results indicate that: 1) IgE antibody to PLA accounts for a high percentage of total IgE protein; 2) the avidities of IgE and IgG antibodies are similar (two of three patients); 3) the valence of IgE antibody approaches two; and (4) IgG antibody can interfere with the measurement of IgE antibody in the PLA RAST.
Modeling Diagnostic Expertise in Cases of Irreducible Uncertainty: The Decision-Aligned Response Model
Cook, David A. , Friedman, Julie , Lorin, Jeffrey D., Rosenzweig, Barry P., Tong, Calvin Ka Wing, Smith, Silas W. , Pusic, Martin V , Pusic, Martin , Lineberry, Matthew , Hatala, Rose

Mayo Clinic

Academic Medicine | December 28, 2022 | Volume: 98 | Issue: 1 | Pages: 88-97

10.1097/acm.0000000000004918 | PMID 36576770 Get It

Abstract Purpose Assessing expertise using psychometric models usually yields a measure of ability that is difficult to generalize to the complexity of diagnoses in clinical practice. However, using an item response modeling framework, it is possible to create a decision-aligned response model that captures a clinician’s decision-making behavior on a continuous scale that fully represents competing diagnostic possibilities. In this proof-of-concept study, the authors demonstrate the necessary statistical conceptualization of this model using a specific electrocardiogram (ECG) example. Method The authors collected a range of ECGs with elevated ST segments due to either ST-elevation myocardial infarction (STEMI) or pericarditis. Based on pilot data, 20 ECGs were chosen to represent a continuum from “definitely STEMI” to “definitely pericarditis,” including intermediate cases in which the diagnosis was intentionally unclear. Emergency medicine and cardiology physicians rated these ECGs on a 5-point scale (“definitely STEMI” to “definitely pericarditis”). The authors analyzed these ratings using a graded response model showing the degree to which each participant could separate the ECGs along the diagnostic continuum. The authors compared these metrics with the discharge diagnoses noted on chart review. Results Thirty-seven participants rated the ECGs. As desired, the ECGs represented a range of phenotypes, including cases where participants were uncertain in their diagnosis. The response model showed that participants varied both in their propensity to diagnose one condition over another and in where they placed the thresholds between the 5 diagnostic categories. The most capable participants were able to meaningfully use all categories, with precise thresholds between categories. Conclusions The authors present a decision-aligned response model that demonstrates the confusability of a particular ECG and the skill with which a clinician can distinguish 2 diagnoses along a continuum of confusability. These results have broad implications for testing and for learning to manage uncertainty in diagnosis.
Imaging of pediatric spine and spinal cord tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee/ASPNR White Paper
Rogers, Samuel N, Udayasankar, Unni , Lai, Hollie , Kadom, Nadja , Guerin, Julie, Shulkin, Barry L , Pruthi, Sumit , Guérin, J. , Malinzak, Michael D. , Shulkin, Barry L. , Poussaint, Tina Young , Patay, Zoltan J , Bag, Asim Kumar

Mayo Clinic

Pediatric Blood & Cancer | December 23, 2022 | Volume: 70 | Issue: S4 | Pages: No page available

10.1002/pbc.30150 | PMID 36562555 Get It

AbstractChildhood spinal tumors are rare. Tumors can involve the spinal cord, the meninges, bony spine, and the paraspinal tissue. Optimized imaging should be utilized to evaluate tumors arising from specific spinal compartments. This paper provides consensus‐based recommendations for optimized imaging of tumors arising from specific spinal compartments at diagnosis, follow‐up during and after therapy, and response assessment.
Zika virus alters osteogenic lineage progression of human mesenchymal stromal cells
Mumtaz, Noreen , Dudakovic, Amel , Nair, Asha, Koedam, Marijke, Leeuwen, Johannes P.T.M. van , Rockx, Barry , Wijnen, André J. van , Eerden, Bram C. J. van der , Rockx, Barry , van der Eerden, Bram C J , van Wijnen, Andre J , Koopmans, Marion

Mayo Clinic

Journal of Cellular Physiology | December 20, 2022 | Volume: 238 | Issue: 2 | Pages: 379-392

10.1002/jcp.30933 | PMID 36538650 Get It

AbstractArboviruses target bone forming osteoblasts and perturb bone remodeling via paracrine factors. We previously reported that Zika virus (ZIKV) infection of early‐stage human mesenchymal stromal cells (MSCs) inhibited the osteogenic lineage commitment of MSCs. To understand the physiological interplay between bone development and ZIKV pathogenesis, we employed a primary in vitro model to examine the biological responses of MSCs to ZIKV infection at different stages of osteogenesis. Precommitted MSCs were infected at the late stage of osteogenic stimulation (Day 7) with ZIKV (multiplicity of infection of 5). We observe that MSCs infected at the late stage of differentiation are highly susceptible to ZIKV infection similar to previous observations with early stage infected MSCs (Day 0). However, in contrast to ZIKV infection at the early stage of differentiation, infection at a later stage significantly elevates the key osteogenic markers and calcium content. Comparative RNA sequencing (RNA‐seq) of early and late stage infected MSCs reveals that ZIKV infection alters the mRNA transcriptome during osteogenic induction of MSCs (1251 genes). ZIKV infection provokes a robust antiviral response at both stages of osteogenic differentiation as reflected by the upregulation of interferon responsive genes (n > 140). ZIKV infection enhances the expression of immune‐related genes in early stage MSCs while increasing cell cycle genes in late stage MSCs. Remarkably, ZIKA infection in early stage MSCs also activates lipid metabolism‐related pathways. In conclusion, ZIKV infection has differentiation stage‐dependent effects on MSCs and this mechanistic understanding may permit the development of new therapeutic or preventative measures for bone‐related effects of ZIKV infection.
Mood and Anxiety Disorders and Suicidality in Patients With Newly Diagnosed Focal Epilepsy
Saporta, A. , Barry, John J., Omotola, Hope, O’Brien, Terence J. , Nadkarni, Siddhartha, Winawer, Melodie R., French, Jacqueline A. , Abou‐Khalil, Bassel , Alldredge, Brian K., Bebin, Martina , Cascino, Gregory D. , Cook, Mark , Detyniecki, Kamil , Dlugos, Dennis , Faught, Edward, Ficker, David M. , Fields, Madeline , Glynn, Simon, Halford, Jonathan J. , Haut, Sheryl R., Hegde, Manu , Kälviäinen, Reetta , Knowlton, Robert C. , Krishnamurthy, Kaarkuzhali Babu , Kwan, Patrick , Lowenstein, Daniel H. , Marcuse, Lara , Meador, Kimford J. , Mintzer, Scott , Pardoe, Heath , Penovich, Patricia , Singh, Rani K. , Szabó, C. Ákos , Szaflarski, Jerzy P. , Burneo, Jorge G. , Project, and the Human Epilepsy, French, Jacqueline A. , Kanner, Andres M, Saporta, Anita S, Kim, Dong H, Altalib, Hamada , Jetté, Nathalie , O'Brien, Terence J, Sperling, Michael, Abou-Khalil, Bassel, Alldredge, Brian, Cook, Mark J , Ficker, David, Gidal, Barry, Gelfand, Michael , Haut, Sheryl, Holmes, Manisha G, Kang, Joon, Klein, Pavel , Krishnamurthy, Kaarkuzhali, Kuzniecky, Ruben , Pardoe, Heath R , Park, Kristen , Szabo, Charles A, Lin Thio, K Liu, Halford, Jonathan J , French, Jacqueline , Meador, Kimford J , Burneo, Jorge G , Kanner, Andres Miguel , Kim, Dong , Sperling, Michael R. , Cole, Andrew J. , Devinsky, Orrin , Gidal, Barry E. , Holmes, Manisha , Kang, Joon Won , Somerville, Ernest , Thio, Liu Lin , Trinka, Eugen , Project, and the Human Epilepsy

Mayo Clinic

Neurology | December 20, 2022 | Volume: 100 | Issue: 11 | Pages: No page available

10.1212/wnl.0000000000201671 | PMID 36539302 Get It